pubmed-article:9157991 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0005775 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0034819 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0017963 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0020852 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C1708096 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0663182 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
pubmed-article:9157991 | lifeskim:mentions | umls-concept:C1321758 | lld:lifeskim |
pubmed-article:9157991 | pubmed:issue | 10 | lld:pubmed |
pubmed-article:9157991 | pubmed:dateCreated | 1997-6-10 | lld:pubmed |
pubmed-article:9157991 | pubmed:abstractText | Animal studies using radiolabeled anti-Tac disulfide-stabilized Fv (dsFv) monoclonal antibody have shown formation of complexes in serum with the soluble alpha subunit of the interleukin 2 receptor alpha (sIL-2R alpha). In this study, we improved the targeting of 125I-labeled anti-Tac dsFv to receptor-positive tumors in the presence of circulating receptor by preinjecting unlabeled humanized anti-Tac IgG antibody (HuTac IgG). We used mice bearing SP2/Tac tumor xenografts that express the IL-2R alpha. A positive correlation was seen between tumor size and the concentration of circulating receptor. Tumor-bearing mice were injected with 125I-labeled anti-Tac dsFv (400 ng), either alone or 15 min after injection of HuTac IgG. The 125I-labeled anti-Tac dsFv formed high molecular weight complexes with the sIL-2R alpha. The fraction of the dsFv present in the complexes increased as tumor size increased (greater sIL-2R alpha levels). The fractions of dsFv in the complexes were 9.9- to 11.6-fold higher when sIL-2R alpha was not blocked with preinjected HuTac IgG. The administration of a 12-fold molar excess of HuTac IgG over sIL-2R alpha resulted in >80% of the 125I activity present as the dsFv rather than in the complexes. Furthermore, the biodistribution of 125I-labeled anti-Tac dsFv was improved by blocking its binding to sIL-2R alpha by preinjecting HuTac IgG. Specifically, in the preinjected group, at 15 min postinjection, the 125I-labeled anti-Tac dsFv levels in tumor increased to 10.8% compared to 5.6% injected dose per gram in the non-preinjected group. In summary, our studies showed that preinjection of HuTac IgG can block the formation of complexes of circulating sIL-2R alpha and 125I-labeled anti-Tac dsFv. This blockade is associated with faster blood clearance, higher tumor uptake, and greater tumor:nontumor ratios of the radiolabeled antibody fragment. | lld:pubmed |
pubmed-article:9157991 | pubmed:language | eng | lld:pubmed |
pubmed-article:9157991 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9157991 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:9157991 | pubmed:month | May | lld:pubmed |
pubmed-article:9157991 | pubmed:issn | 0008-5472 | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:PastanII | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:KobayashiHH | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:WaldmannT ATA | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:OOIS KSK | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:KimM KMK | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:CarrasquilloJ... | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:PaikC HCH | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:SunB FBF | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:WebberK OKO | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:YooT MTM | lld:pubmed |
pubmed-article:9157991 | pubmed:author | pubmed-author:DrummDD | lld:pubmed |
pubmed-article:9157991 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:9157991 | pubmed:day | 15 | lld:pubmed |
pubmed-article:9157991 | pubmed:volume | 57 | lld:pubmed |
pubmed-article:9157991 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:9157991 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:9157991 | pubmed:pagination | 1955-61 | lld:pubmed |
pubmed-article:9157991 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:meshHeading | pubmed-meshheading:9157991-... | lld:pubmed |
pubmed-article:9157991 | pubmed:year | 1997 | lld:pubmed |
pubmed-article:9157991 | pubmed:articleTitle | Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG. | lld:pubmed |
pubmed-article:9157991 | pubmed:affiliation | Department of Nuclear Medicine, National Cancer Institute, NIH, Bethesda, Maryland 20892-1180, USA. | lld:pubmed |
pubmed-article:9157991 | pubmed:publicationType | Journal Article | lld:pubmed |